CDKN2A mutations in multiple primary melanomas

New England Journal of Medicine

Volumn 338, Issue 13, 1998, Pages 879-887

  Monzon, Jose ^a   Liu, Ling ^a   Brill, Herbert ^a   Goldstein, Alisa M ^b   Tucker, Margaret A ^b   From, Lynn ^a   McLaughlin, John ^a   Hogg, David ^a   Lassam, Norman J ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b NATIONAL CANCER INSTITUTE   (United States)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16;

ADULT; AGED; ARTICLE; CANCER SUSCEPTIBILITY; CLINICAL ARTICLE; DNA SEQUENCE; FEMALE; GENE MUTATION; HUMAN; MALE; MELANOMA; MULTIPLE CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ADULT; AGED; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, P16; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASMS, MULTIPLE PRIMARY; PEDIGREE; SKIN NEOPLASMS;

EID: 0032568258     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199803263381305     Document Type: Article

References (36)

1. Birch JM. Genetic determinants of cancer in man. In: Waring MJ, Ponder B, eds. Biology of carcinogenesis. Lancaster, Pa.: MTP Press, 1987:165-89.
2. Schottenfeld D. Multiple primary cancers. In: Schottenfeld D, Fraumeni J, eds. Cancer epidemiology and prevention. 2nd ed. New York: Oxford University Press, 1996:1370-87.
3. Carey TE. Field cancerization: are multiple primary cancers monoclonal or polyclonal? Ann Med 1996;28:183-8.
4. Rigel DS, Friedman RJ, Kopf AW. The incidence of malignant melanoma in the United States: issues as we approach the 21st century. J Am Acad Dermatol 1996;34:839-47.
5. Rigel DS. Malignant melanoma: incidence issues and their effect on diagnosis and treatment in the 1990s. Mayo Clin Proc 1997;72:367-71.
6. Giles G, Staples M, McCredie M, Coates M. Multiple primary melanomas: an analysis of cancer registry data from Victoria and New South Wales. Melanoma Res 1995;5:433-8.
7. Brobeil A, Rapaport D, Wells K, et al. Multiple primary melanomas: implications for screening and follow-up programs for melanoma. Ann Surg Oncol 1997;4:19-23.
8. Gupta BK, Piedmonte MR, Karakousis CP. Attributes and survival patterns of multiple primary cutaneous malignant melanoma. Cancer 1991;67:1984-9.
9. Moseley HS, Giuliano AE, Storm FK III, Clark WH, Robinson DS, Morton DL. Multiple primary melanoma. Cancer 1979;43:939-44.
10. Frank W, Rogers GS. Melanoma update: second primary melanoma. J Dermatol Surg Oncol 1993;19:427-30.
11. Slingluff, CL Jr, Vollmer RT, Seigler HF. Multiple primary melanoma: incidence and risk factors in 283 patients. Surgery 1993;113:330-9.
12. Kang S, Barnhill RL, Mihm MC Jr, Sober AJ. Multiple primary cutaneous melanomas. Cancer 1992;70:1911-6.
13. Reimer RR, Clark WH Jr, Greene MH, Ainsworth AM, Fraumeni JF Jr. Precursor lesions in familial melanoma: a new genetic preneoplastic syndrome. JAMA 1978;239:744-6.
14. Greene MH, Clark WH Jr, Tucker MA, Kraemer KH, Elder DE, Fraser MC. High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med 1985;102:458-65.
15. Goldstein AM, Tucker MA. Genetic epidemiology of familial melanoma. Dermatol Clin 1995;13:605-12.
16. Lynch HT, Fusaro RM, Lynch J. Hereditary cancer in adults. Cancer Detect Prev 1995;19:219-33.
17. Goldstein AM, Tucker MA. Screening for CDKN2A mutations in hereditary melanoma. J Natl Cancer Inst 1997;89:676-8.
18. INK4 mutations. N Engl J Med 1995;333:970-4.
19. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
20. Herwig S, Strauss M. The retinoblastoma protein: a master regulator of cell cycle, differentiation and apoptosis. Eur J Biochem 1997;246:581-601.
21. Kamb A. Cell-cycle regulators and cancer. Trends Genet 1995;11:136-40.
22. Barrel PL, Fields S. Analyzing protein-protein interactions using two-hybrid system. Methods Enzymol 1995;254:241-63.
23. Smith-Sorensen B, Hovig E. CDKN2A (p16INK4A) somatic and germline mutations. Hum Mutat 1996;7:294-303.
24. Liu L, Lassam NJ, Slingerland JM, et al. Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma. Oncogene 1995;11:405-12.
25. Parry D, Peters G. Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma. Mol Cell Biol 1996;16:3844-52.
26. Walker GJ, Hussusian CJ, Flores JF, et al. Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Mol Genet 1995;4:1845-52.
27. Holland EA, Beaton SC, Becker TM, et al. Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene 1995;11:2289-94.
28. Ranade K, Hussussian CJ, Sikorski RS, et al. Mutations associated with familial melanoma impair p16INK4 function. Nat Genet 1995;10:114-6.
29. Lilischkis K, Sarcevic B, Kennedy C, Warlters A, Sutherland RL. Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity. Int J Cancer 1996;66:249-54.
30. Koh J, Enders GH, Dynlacht BD, Harlow E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 1995;375:506-10.
31. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994;8:15-21.
32. Zuo L, Weger J, Yang Q, et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996;12:97-9.
33. Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms in patients with retinoblastoma. Br J Cancer 1986;53:661-71.
34. Traboulsi EI, Zimmerman LE, Manz HJ. Cutaneous malignant melanoma in survivors of heritable retinoblastoma. Arch Ophthalmol 1988;106:1059-61.
35. Eng C, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 1993;85:1121-8.
36. Bataille V, Hiles R, Bishop JA. Retinoblastoma, melanoma and the atypical mole syndrome. Br J Dermatol 1995;132:134-8.